Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCO-101 plus FOLFIRI in acquired FOLFIRI-resistant metastatic colorectal cancer
2019-003779-20Phase 2Completed
- Sponsor
- Scandion Oncology
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sco-101 in colorectal cancer (CRC), sponsored by Scandion Oncology. Primary endpoints: Safety and tolerability and Maximum tolerated dose. Started Oct 2019; status: completed.
02
Drugs
sco-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-003779-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003779-20.